Armata Pharmaceuticals (ARMP) Cash & Equivalents (2013 - 2026)

Armata Pharmaceuticals has reported Cash & Equivalents for 14 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 58.93% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 58.93% YoY) and the FY2025 annual result came in at $8.7 million, down 6.49% from the prior year.
• Cash & Equivalents declined to $4.8 million in Q1 2026 per ARMP's latest filing, from $8.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $46.4 million in Q1 2022 and troughed at $4.3 million in Q2 2025.
• A 5-year average of $19.6 million and a median of $14.9 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 111.99% in 2024, then sank 83.61% in 2025.
• Over 5 years, Cash & Equivalents stood at $14.9 million in 2022, then dropped by 8.95% to $13.5 million in 2023, then plunged by 31.29% to $9.3 million in 2024, then decreased by 6.49% to $8.7 million in 2025, then slumped by 44.75% to $4.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.8 million, $8.7 million, and $14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.